A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy

This dose-ranging study was conducted to identify the optimal fixed dose of lipegfilgrastim compared with pegfilgrastim 6.0 mg for the provision of neutrophil support during myelosuppressive chemotherapy in patients with breast cancer. A phase 2 study was conducted in which 208 chemotherapy-naive pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchner, Anton, Elsässer, Reiner, Bias, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196040/
https://www.ncbi.nlm.nih.gov/pubmed/25261291
http://dx.doi.org/10.1007/s10549-014-3120-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196040/
https://www.ncbi.nlm.nih.gov/pubmed/25261291
http://dx.doi.org/10.1007/s10549-014-3120-6

Ejemplares similares